EXHIBIT 3

COVINGTON & BURLING LLP

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202.662.6000
FAX 202.662.6291
WWW.COV.COM

BEIJING
BRUSSELS
LONDON
NEW YORK
SAN DIEGO
SAN FRANCISCO
SILICON VALLEY
WASHINGTON

DAVID J. SHAW
TEL 202.662.5094
FAX 202.778.5094
DSHAW @ COV.COM

September 18, 2012

VIA HAND DELIVERY

June Im, Esq.
Federal Trade Commission
Bureau of Competition
601 New Jersey Avenue, N.W.
Washington, DC 20001

Re: File No. 121-0062: ViroPharma

Dear June:

Please find enclosed responses, in part, to Specification 20, 21, 23, 28, and 35.

Please let me know if you have any questions.

Sincerely,

David J. Shaw
Associate

Enclosure

CC: Melanie Brown, Esq.

ViroPharma's Responses, in part, to Specifications 20, 21, 23, 28, & 35

ViroPharma hereby incorporates by reference each and every objection stated in the General Objections.

SPECIFICATION 20: Identify each ViroPharma employee, representative, agent and consultant involved in the Vancocin FDA Submissions, and for each individual identify:

A. his/her role;
B. his/her current position with ViroPharma or current employer; and
C. his/her position and/or employer at the time of his/her involvement.

Response:

ViroPharma is non-hierarchical and so formal titles and positions are rarely used and may not be reflected in subsequently produced documents. Additionally, ViroPharma does not formally track where former employees currently work, so that information is not included.

Listed below are those ViroPharma employees and agents who made important decisions or significant contributions regarding the FDA Submissions.

Name	Role	Current Position	Position During Involvement
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]

	Vancocin		
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]

[redacted]



SPECIFICATION 21: Identify ViroPharma's reason(s) for filing the Vancocin FDA Submissions and submit all documents relating to your response.

Response:

ViroPharma petitioned the FDA in order to raise significant scientific, legal, and regulatory issues that arose in connection with the FDA's consideration and adoption of new bioequivalence standards for approving generic versions of Vancocin. The Vancocin FDA Submissions were generally reactive to shifting FDA positions on bioequivalence standards for generic versions of Vancocin, specific FDA administrative actions (e.g., the convening of advisory committee meetings, the publication of draft guidance), and new information made

available to ViroPharma by FDA (in pieces and over time) as a result of a court order following FOIA litigation, from tests performed by ViroPharma, and from the scientific community generally. With regard to the documents relating to this Specification 21, please refer to VP_00000034–23655, VP0025337–730 for the scientific, legal and regulatory issues raised by the FDA Submissions.

SPECIFICATION 23: Identify and describe any assessment ViroPharma made related to the merits of its Vancocin FDA Submissions, including the names of the individuals responsible for such assessments, and submit all documents relating to your response.

Response:

ViroPharma incorporates herein by reference its Response to Specification 21. Materials provided in response to Specification 21 include ViroPharma submissions to FDA and other documents setting forth ViroPharma's views on the merits of its positions on the issues raised by the Vancocin FDA Submissions. ViroPharma will identify any further specific non-privileged assessments as it continues its review of documents.

SPECIFICATION 28: Identify and describe any assessment ViroPharma made related to the merits of its (1) FDA Litigation; (2) FOIA Litigation; and (3) Precose Litigation. Include the names of the individuals responsible for such assessments, and submit all documents relating to your response.

Response:

ViroPharma incorporates herein by reference its Response to Specification 21. Materials provided in response to Specification 21 include ViroPharma submissions to FDA and other documents setting forth ViroPharma's views on the merits of its positions on the issues raised by the the FDA Litigation, FOIA Litigation, and Precose Litigation. ViroPharma will identify any further specific non-privileged assessments as it continues its review of documents.

SPECIFICATION 35: Identify all code names and other internal Company identifiers used to refer to Vancocin, any Vancocin related transaction, the Vancocin FDA Submissions or any litigation with the FDA.

Response:

[redacted]